Please ensure Javascript is enabled for purposes of website accessibility
Home / Products / Research Biosimilar

Research Grade Lerdelimumab (DHF46301)

Host species:Human
Isotype:IgG4-lambda
Applications:Research Grade Biosimilar
Expression system:Mammalian Cells
Overview

Catalog No.

DHF46301

Expression system

Mammalian Cells

Species reactivity

Human

Host species

Human

Isotype

IgG4-lambda

Clonality

Monoclonal

Target

Glioblastoma-derived T-cell suppressor factor, TGF-beta-2, LAP, G-TSF, TGFB2, Cetermin, Transforming growth factor beta-2 proprotein

Concentration

1 mg/ml

Endotoxin level

Please contact with the lab for this information.

Purity

>95% as determined by SDS-PAGE.

Purification

Protein A/G purified from cell culture supernatant.

Accession

P61812

Applications

Research Grade Biosimilar

Form

Liquid

Storage buffer

0.01M PBS, pH 7.4.

Stability and Storage

Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.

Alternative Names

CAT-152, Trabio, CAS: 285985-06-0

Clone ID

Lerdelimumab

Data Image
  • SDS-PAGE
    SDS PAGE for Lerdelimumab
  • Bioactivity
    Detects TGFB2 in indirect ELISAs.
References

A phase III study of subconjunctival human anti-transforming growth factor beta(2) monoclonal antibody (CAT-152) to prevent scarring after first-time trabeculectomy, PMID: 17908591

CAT-152 Trabeculectomy Study, PMID: 17908596

Evaluation of anti-TGF-beta2 antibody as a new postoperative anti-scarring agent in glaucoma surgery, PMID: 12882787

Factors affecting the outcome of trabeculectomy: an analysis based on combined data from two phase III studies of an antibody to transforming growth factor beta2, CAT-152, PMID: 17719641

Gateways to clinical trials, PMID: 12808477

Large- and small-molecule inhibitors of transforming growth factor-beta signaling, PMID: 16784021

Lerdelimumab, PMID: 12001808

Short-term exposure to transforming growth factor beta induces long-term fibrotic responses, PMID: 16934251

Strategies for TGF-beta modulation: a review of recent patents, PMID: 19939191

Technology evaluation: lerdelimumab, Cambridge Antibody Technology, PMID: 12772512

TGF-beta(2) antibody in trabeculectomy, PMID: 19118706

TGF-beta2-induced matrix modification and cell transdifferentiation in the human lens capsular bag, PMID: 12091431

Trabeculectomy outcomes, PMID: 18519074

Datasheet

Document Download

Research Grade Lerdelimumab.pdf

 

$ 328
Product specifications
100 μg 328 1 mg 1314

Contact Information

Order: order@antibodysystem.com

Mail: support@antibodysystem.com

Distributor list

For research use only. Not for human or drug use.

Need help with your order?

Find out more about placing an order here

Research Grade Lerdelimumab [DHF46301]
Terms of sale Website terms of use Cookie policy Privacy
Copyright © 2024 AntibodySystem SAS. All Rights Reserved.            All Products are for Research Use Only